

Colorectal Cancer: Update Bulletin #1

<https://marketpublishers.com/r/C40846BE11CEN.html>

Date: November 2017

Pages: 0

Price: US\$ 1,095.00 (Single User License)

ID: C40846BE11CEN

Abstracts

This edition presents the views and insights from three world leading key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the colorectal cancer (CRC) market, including; Symphogen announcing detailed results from its randomised Phase II study with SYM004 compared to investigator-choice chemotherapy or best-supportive-care, in patients with advanced metastatic CRC and acquired resistance to anti-EGFR monoclonal antibodies (mAbs); Array BioPharma and Pierre Fabre announcing safety results and initial clinical activity data from the safety lead-in phase of the Phase III BEACON CRC study, which is assessing the safety and efficacy of binimetinib, encorafenib and cetuximab (BIN/ENC/CTX) in patients with BRAF-mutant CRC whose disease has progressed after one or two prior regimens in the metastatic setting; and The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopting a positive opinion, recommending the granting of a marketing authorisation for Mvasi, a biosimilar version of Avastin (bevacizumab) from Amgen and Allergan, intended for the treatment of carcinoma of the colon or rectum and other indications.

Business Questions:

Are KOLs intrigued by SYM004's mechanism of action?

Were KOLs disappointed with the overall result from SYM004's Phase II study, and did they think that the positive signal in certain patients warrants further investigation?

Do KOLs believe that the design of the Phase II study for SYM004 contributed to its failure?

What are the next steps for Symphogen and SYM004? Terminate development

or confirm the positive efficacy signal seen in the Phase II study for SYM004 in a larger Phase III study?

Where do KOLs believe that SYM004 will be used in the treatment of mCRC, and which products will it displace?

Do KOLs believe that early data from the Phase III BEACON study, which is assessing the binimetinib/encorafenib/cetuximab (BIN/ENC/CTX) triplet combination, supports previously published data from the Southwest Oncology Group?

What do KOLs think about the safety and early efficacy data for BIN/ENC/CTX; promising, or too early to tell?

What will BIN/ENC/CTX need to show in order to compete with current treatment regimens: improvements in OS, ORR, and PFS, or all of the above?

Are KOLs happy to have access to biosimilars, or will remaining concerns slow down uptake of bevacizumab biosimilars in the mCRC setting?

What do KOLs think about the non-medical switching of patients from Avastin to bevacizumab biosimilars?

Will the Centers for Medicare & Medicaid Services' (CMS) announcement that all biosimilars will receive their own J code lead to greater biosimilar uptake?

I would like to order

Product name: Colorectal Cancer: Update Bulletin #1

Product link: <https://marketpublishers.com/r/C40846BE11CEN.html>

Price: US\$ 1,095.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C40846BE11CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970